Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer
Clinical trial NCT04182724 · UNKNOWN
Trial details
- NCT number
- NCT04182724
- Sponsor
- Chinese PLA General Hospital
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-12
- Primary completion
- 2021-05-12
- Enrollment
- 57
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.